Navigation Links
Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
Date:2/19/2013

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, has been invited to participate in Lazard Capital Market's 5th Annual Medical Technology Snowbird Conference. The conference is being held at the Cliff Lodge Snowbird Ski & Summer Resort in Snowbird, Utah from February 27 - March 1, 2013.

Vermillion's Interim CEO Bruce A. Huebner is scheduled to participate in one-on-one meetings with institutional investors to be held throughout the day on Wednesday, February 27, 2013. He will discuss the company's initiatives to drive market adoption of OVA1®, the first FDA-cleared blood test for the pre-surgical diagnosis of ovarian masses using a unique multi-marker algorithm.  

For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your Lazard representative.

About Lazard Capital Markets
Lazard Capital Markets is a growth-oriented full service broker-dealer with a unique position in today's capital markets. The company's institutional clients value its focused, action-oriented proprietary research, which is based on deep domain expertise in the Healthcare, Consumer, Energy, Technology and Transportation sectors. The company's Sales and Trading professionals have long-standing relationships with over 600 institutional accounts, and, with an average of 15 years of experience, have an intimate knowledge of our clients' investment objectives. Finally, the company's relationship with Lazard, an international investment bank, which operates in 39 cities across 21 countries, provides the company with unparalleled global connections. For more information, visit www.lazardcap.com.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860
vrml@liolios.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. ViroPharma to Participate in Two December Healthcare Investor Conferences
6. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
7. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
8. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
9. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
10. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... San Diego, CA (PRWEB) , ... May 20, 2016 , ... ... announce that 10 of its most experienced veterinary clients have treated over 100 of ... this cutting edge technology to provide the highest level of care for their patients. ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in ... office building is complete. The new structure adds a third office building to the ... USA purchased 2.4 acres of land, along with office space adjacent to the ...
(Date:5/19/2016)... May 19, 2016 ... (OTC PINK: RGBPP) announced today initiation of a ... cord blood based cancer immunotherapeutic product leveraging its ... Regen described a generation of cord blood derived ... gene silencing.  The product in development will be ...
(Date:5/18/2016)... YORK , May 18, 2016 ... but it does not mean that there are no opportunities ... Threshold Pharmaceuticals Inc. (NASDAQ: THLD ), Seattle Genetics ... CHMA ), and Ophthotech Corp. (NASDAQ: OPHT ... trading alerts at: http://www.activewallst.com/ ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
Breaking Biology News(10 mins):